Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation

JCO Precis Oncol. 2022 Jan:6:e2100271. doi: 10.1200/PO.21.00271.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anaplastic Lymphoma Kinase / physiology
  • Benzamides / therapeutic use*
  • Chromosomes, Human, Pair 2 / genetics
  • Cytokines / genetics
  • Genetic Variation
  • Germ Cells
  • Humans
  • Indazoles / therapeutic use*
  • Infant
  • Male
  • Neuroblastoma / drug therapy*
  • Neuroblastoma / genetics
  • Neuroblastoma / secondary
  • Protein Kinase Inhibitors / therapeutic use*
  • Receptor, trkA / physiology

Substances

  • ALKAL2 protein, human
  • Benzamides
  • Cytokines
  • Indazoles
  • NTRK1 protein, human
  • Protein Kinase Inhibitors
  • Anaplastic Lymphoma Kinase
  • Receptor, trkA
  • entrectinib